ESR1 and breast cancer: When compared with ER+ breast cancers, loss-of-function mutations in the retinoblastoma tumor suppressor RB1 (RB) are more common in TNBC (7% versus <4%), and RB pathway alterations have been reported in up to 30% of TNBC (20, 21).